Hyperfine (NASDAQ:HYPR – Get Free Report) posted its earnings results on Tuesday. The company reported ($0.09) EPS for the quarter, hitting analysts’ consensus estimates of ($0.09), FiscalAI reports. Hyperfine had a negative return on equity of 95.09% and a negative net margin of 262.29%.The business had revenue of $3.90 million during the quarter, compared to analyst estimates of $3.54 million.
Here are the key takeaways from Hyperfine’s conference call:
- Hyperfine posted Q1 2026 revenue of $3.9 million, up 83% year over year, making it the company’s second-highest quarter ever and supported by sales across all three business verticals.
- Gross margin expanded to 50.7%, the third straight quarter above 50%, while net cash burn improved to $8.8 million from $10.1 million a year ago, showing better operating leverage and spending discipline.
- Management reiterated full-year 2026 guidance for $20 million-$22 million in revenue, 50%-55% gross margin, and $26 million-$28 million in cash burn, while saying the business should strengthen through the year.
- The company highlighted several commercial and regulatory milestones, including CE and UKCA marks for the next-generation system and Optive AI software, more than 50% enrollment in the Contrast PMR study, and strong reception to its advanced DWI software.
- Hyperfine sees growth coming from hospitals/IDNs, neurology offices, and international markets, with an expanding pipeline of multi-site IDN deals and plans to launch in Europe in the third quarter; the company also discussed future use in OR and angio-suite settings.
Hyperfine Trading Down 7.8%
HYPR stock traded down $0.14 during trading on Wednesday, reaching $1.60. The stock had a trading volume of 497,126 shares, compared to its average volume of 536,391. The firm has a market cap of $156.24 million, a PE ratio of -3.63 and a beta of 1.42. The stock’s 50 day moving average is $1.27 and its two-hundred day moving average is $1.15. Hyperfine has a 52 week low of $0.53 and a 52 week high of $2.22.
Insider Activity
Institutional Investors Weigh In On Hyperfine
Hedge funds have recently modified their holdings of the business. EP Wealth Advisors LLC bought a new position in Hyperfine in the 4th quarter worth $34,000. Millennium Management LLC purchased a new stake in Hyperfine in the fourth quarter worth about $55,000. Cerity Partners LLC purchased a new stake in Hyperfine in the fourth quarter worth about $59,000. XTX Topco Ltd raised its stake in shares of Hyperfine by 47.9% in the fourth quarter. XTX Topco Ltd now owns 80,735 shares of the company’s stock worth $79,000 after buying an additional 26,165 shares during the period. Finally, Bridgeway Capital Management LLC raised its stake in shares of Hyperfine by 50.2% in the fourth quarter. Bridgeway Capital Management LLC now owns 119,700 shares of the company’s stock worth $117,000 after buying an additional 40,000 shares during the period. Institutional investors own 15.03% of the company’s stock.
Analyst Upgrades and Downgrades
HYPR has been the topic of several recent analyst reports. B. Riley Financial reaffirmed a “buy” rating on shares of Hyperfine in a research report on Wednesday. BTIG Research started coverage on shares of Hyperfine in a research note on Wednesday, April 29th. They set a “buy” rating and a $2.00 target price on the stock. Lake Street Capital raised their price target on shares of Hyperfine from $2.00 to $2.50 and gave the company a “buy” rating in a report on Thursday, March 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Hyperfine in a research note on Tuesday, April 21st. Finally, Zacks Research raised shares of Hyperfine to a “hold” rating in a report on Thursday, March 19th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Hyperfine currently has an average rating of “Hold” and an average price target of $1.59.
Read Our Latest Stock Analysis on Hyperfine
About Hyperfine
Hyperfine, Inc (NASDAQ: HYPR) is a medical technology company focused on expanding access to advanced neuroimaging through its portable magnetic resonance imaging (MRI) system. The company’s flagship product, Swoop®, is designed to enable bedside MRI scanning in a wide range of clinical environments, including emergency departments, intensive care units and outpatient clinics. By leveraging a compact, high-performance permanent magnet and a custom-designed gradient system, Hyperfine aims to reduce the logistical and financial barriers associated with traditional, large-scale MRI installations.
The Swoop system features a lightweight, wheeled design that can be maneuvered directly to a patient’s bedside, allowing clinicians to conduct diagnostic imaging without the need to transport critically ill or immobile patients.
Featured Articles
- Five stocks we like better than Hyperfine
- Reading the Stripes: Is The Industrial Recession Over?
- Micron Investors Face a High-Stakes Moment After the Latest Rally
- How Bad Could Tesla’s Cybertruck Recall Be for Shares?
- Dream Finders Homes’ Hostile Bid Creates a Dual Squeeze Play
Receive News & Ratings for Hyperfine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperfine and related companies with MarketBeat.com's FREE daily email newsletter.
